ADVA
4.11.2021 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that CSC – IT Center for Science, which operates the Finnish University and Research Network (FUNET), has set an industry record by transporting 800Gbit/s farther than ever before over a live network. Using the ADVA FSP 3000 TeraFlex™ CoreChannel™ , FUNET’s succeeded in transmitting data at 800Gbit/s on links exceeding 2,000km. The field trial shows how network operators can leverage new value in existing large-scale infrastructure and how FUNET can empower the Nordics’ academics and scientists to achieve even more. Harnessing 140GBd sub-carrier technology, ADVA’s new CoreChannel™ sled leverages 150GHz channel spacing, enabling TeraFlex™ to deliver the market’s longest reach for a single-channel 800Gbit/s solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005050/en/
“ADVA’s FSP 3000 TeraFlex™ CoreChannel™ at 800Gbit/s speed delivered impressive reach during our tests and was stable throughout the month-long test period when we ran it on our nationwide ADVA open line system . The new 800Gbit/s channel technology will give us more flexibility to choose optimum modulation per use case to improve spectral efficiency. And, more importantly, it maps efficiently to 400GbE client services,” said Jani Myyry, senior network specialist, CSC/FUNET. “This field trial demonstrates that our network can smoothly support future requirements and deliver even more to our users in the Finnish research and education community. It also will strengthen our confidence that the first multi-Terabit services we aim to deliver early next year together with other Nordic research and education networks can be implemented successfully.”
With the addition of the new CoreChannel™ sled , ADVA’s FSP 3000 TeraFlex™ is the industry’s most efficient high-capacity open optical terminal for all applications from metro to submarine links. Now trials in the ultra-long-haul FUNET transport system have proven its compatibility with deployed infrastructure and shown that it offers excellent performance in a live flexgrid network built with multi-degree ROADMs and RAMAN amplifiers. TeraFlex™ CoreChannel™ also delivers industry-leading SNR requirements, making it resilient to transmission impairments. Featuring multi-rate client support, the CoreChannel™ sled can also transport any mix of 400GbE, 100GbE and 10GbE services, protecting investment and providing complete flexibility.
“It’s fantastic to see our FSP 3000 TeraFlex™ with CoreChannel™ sled pass this major test with such flying colors. Even over the FUNET network’s longest distances, the solution surpassed expectations and showed how incredible speeds are now possible at the lowest possible cost per bit per kilometer,” commented Cornelius Fürst, director, product line management, ADVA. “One of the reasons our FSP 3000 TeraFlex™ CoreChannel™ is able to provide such great long-haul performance is that it carries data at 800Gbit/s using a 150GHz window. Not only does this help to reduce complexity and avoid stranded bandwidth, but it also makes the technology future-proof. 150GHz is the channel spacing that offers the best balance between fiber capacity and optical reach. That’s why it’s gaining traction across the industry and why our open FSP 3000 TeraFlex™ CoreChannel™ sled is ready for new innovation further down the line.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About CSC – IT Center for Science Ltd.
CSC – IT Center for Science is a Finnish center of expertise in information technology owned by the Finnish state and higher education institutions. We provide internationally high-quality ICT expert services for higher education institutions, research institutes, culture, public administration and enterprises. For more information, please visit www.csc.fi
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005050/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom